MS market to reach $20 billion in 2023 boosted by five new therapies

8 August 2014

The forecast launch of five immunomodulatory therapies for relapsing forms of multiple sclerosis will help drive total sales across the MS market in the USA, France, Germany, Italy, Spain, UK and Japan to more than $20 billion in 2023, reflecting 4% annual growth from 2013.

Decision Resources Group’s Pharmacor report looked at the launch of US biotech firm Biogen Idec (Nasdaq: BIIB) Plegridy (peginterferon beta-1a), Roche (ROG: SIX)/Genentech's ocrelizumab, Biogen Idec (Nasdaq: BIIB)/AbbVie's (NYSE: ABBV) daclizumab, Teva Pharmaceutical Industries (NYSE: TEVA) / Swedish partner Active Biotech’s (Nasdaq OMX:ACTI) Nerventra (laquinimod) and Receptos' RPC-1063, and the expected US approval of Genzyme/Sanofi/Bayer HealthCare's Lemtrada (alemtuzumab).

In addition it found that future generics and projected biosimilar competition will cause major-market sales to contract in the latter part of the study period from a 2018 peak of over $22 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >